Autolus Therapeutics PLC (AUTL)
4.06
-0.01
(-0.25%)
USD |
NASDAQ |
May 07, 15:05
Autolus Therapeutics Research and Development Expense (Quarterly): 25.16M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 25.16M |
| September 30, 2023 | 37.24M |
| June 30, 2023 | 36.74M |
| March 31, 2023 | 31.34M |
| December 31, 2022 | 7.548M |
| September 30, 2022 | 37.63M |
| June 30, 2022 | 38.21M |
| March 31, 2022 | 33.96M |
| December 31, 2021 | 15.68M |
| September 30, 2021 | 32.29M |
| Date | Value |
|---|---|
| June 30, 2021 | 32.13M |
| March 31, 2021 | 30.73M |
| December 31, 2020 | 38.73M |
| September 30, 2020 | 33.54M |
| June 30, 2020 | 31.33M |
| March 31, 2020 | 31.29M |
| December 31, 2019 | 29.37M |
| September 30, 2019 | 27.31M |
| June 30, 2019 | 26.17M |
| March 31, 2019 | 22.56M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
7.548M
Minimum
Dec 2022
38.73M
Maximum
Dec 2020
30.34M
Average
31.34M
Median
Mar 2023